How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.